These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 18049471)

  • 21. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.
    Rameix-Welti MA; Agou F; Buchy P; Mardy S; Aubin JT; Véron M; van der Werf S; Naffakh N
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3809-15. PubMed ID: 16940075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase.
    Wang YT; Chan CH; Su ZY; Chen CL
    Biophys Chem; 2010 Mar; 147(1-2):74-80. PubMed ID: 20045243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005.
    Ferraris O; Kessler N; Valette M; Lina B
    Vaccine; 2006 Nov; 24(44-46):6656-9. PubMed ID: 16797804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
    Hayden F; Klimov A; Tashiro M; Hay A; Monto A; McKimm-Breschkin J; Macken C; Hampson A; Webster RG; Amyard M; Zambon M
    Antivir Ther; 2005; 10(8):873-7. PubMed ID: 16430192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of neuraminidase inhibitors to combat pandemic influenza.
    Democratis J; Pareek M; Stephenson I
    J Antimicrob Chemother; 2006 Nov; 58(5):911-5. PubMed ID: 16956904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.
    Farrukee R; Mosse J; Hurt AC
    Expert Rev Anti Infect Ther; 2013 Nov; 11(11):1135-45. PubMed ID: 24093683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of antiviral agents and other measures in an influenza pandemic.
    Groeneveld K; van der Noordaa J
    Neth J Med; 2005 Oct; 63(9):339-43. PubMed ID: 16244380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral drugs for influenza 2012-2013.
    Med Lett Drugs Ther; 2012 Dec; 54(1405):97-8. PubMed ID: 23223245
    [No Abstract]   [Full Text] [Related]  

  • 29. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
    Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
    Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
    Wang SQ; Du QS; Chou KC
    Biochem Biophys Res Commun; 2007 Mar; 354(3):634-40. PubMed ID: 17266937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.
    Ferraris O; Lina B
    J Clin Virol; 2008 Jan; 41(1):13-9. PubMed ID: 18055254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antiviral agents for influenza].
    Mitamura K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():401-6. PubMed ID: 17455653
    [No Abstract]   [Full Text] [Related]  

  • 33. Pandemic flu vaccine: are we doing enough?
    Campbell JD
    Clin Pharmacol Ther; 2007 Dec; 82(6):633-5. PubMed ID: 17998908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
    Hurt AC; Barr IG; Komadina N; Hampson AW
    Virus Res; 2004 Jul; 103(1-2):79-83. PubMed ID: 15163493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.
    Abed Y; Baz M; Boivin G
    J Infect Dis; 2009 Jan; 199(2):180-3. PubMed ID: 19046066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of influenza neuraminidase inhibitors.
    Abdel-Magid AF; Maryanoff CA; Mehrman SJ
    Curr Opin Drug Discov Devel; 2001 Nov; 4(6):776-91. PubMed ID: 11899618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
    Bauer K; Richter M; Wutzler P; Schmidtke M
    Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
    Magano J
    Chem Rev; 2009 Sep; 109(9):4398-438. PubMed ID: 19537777
    [No Abstract]   [Full Text] [Related]  

  • 39. Swine flu outbreak. What role for antiviral drugs?
    Couzin-Frankel J
    Science; 2009 May; 324(5928):705. PubMed ID: 19423784
    [No Abstract]   [Full Text] [Related]  

  • 40. Computational analysis and modeling the effectiveness of 'Zanamivir' targeting neuraminidase protein in pandemic H1N1 strains.
    Gupta SK; Gupta SK; Smita S; Srivastava M; Lai X; Schmitz U; Rahman Q; Wolkenhauer O; Vera J
    Infect Genet Evol; 2011 Jul; 11(5):1072-82. PubMed ID: 21463714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.